ATE212619T1 - Alpha-amino sulfonyl hydroxamsäure als matrix metalloproteinase inhibitoren - Google Patents

Alpha-amino sulfonyl hydroxamsäure als matrix metalloproteinase inhibitoren

Info

Publication number
ATE212619T1
ATE212619T1 AT97910851T AT97910851T ATE212619T1 AT E212619 T1 ATE212619 T1 AT E212619T1 AT 97910851 T AT97910851 T AT 97910851T AT 97910851 T AT97910851 T AT 97910851T AT E212619 T1 ATE212619 T1 AT E212619T1
Authority
AT
Austria
Prior art keywords
matrix metalloproteinase
alpha
metalloproteinase inhibitors
hydroxamic acid
amino sulfonyl
Prior art date
Application number
AT97910851T
Other languages
German (de)
English (en)
Inventor
Martha A Warpehoski
Mark A Mitchell
E Jon Jacobsen
Original Assignee
Upjohn Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Upjohn Co filed Critical Upjohn Co
Application granted granted Critical
Publication of ATE212619T1 publication Critical patent/ATE212619T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/22Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms
    • C07C311/29Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/15Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C311/16Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom
    • C07C311/19Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom to an acyclic carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04Indoles; Hydrogenated indoles
    • C07D209/10Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D209/20Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals substituted additionally by nitrogen atoms, e.g. tryptophane

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Indole Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT97910851T 1996-10-22 1997-10-20 Alpha-amino sulfonyl hydroxamsäure als matrix metalloproteinase inhibitoren ATE212619T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2958596P 1996-10-22 1996-10-22
PCT/US1997/018235 WO1998017645A1 (en) 1996-10-22 1997-10-20 α-AMINO SULFONYL HYDROXAMIC ACIDS AS MATRIX METALLOPROTEINASE INHIBITORS

Publications (1)

Publication Number Publication Date
ATE212619T1 true ATE212619T1 (de) 2002-02-15

Family

ID=21849807

Family Applications (1)

Application Number Title Priority Date Filing Date
AT97910851T ATE212619T1 (de) 1996-10-22 1997-10-20 Alpha-amino sulfonyl hydroxamsäure als matrix metalloproteinase inhibitoren

Country Status (9)

Country Link
US (1) US5804593A (https=)
EP (1) EP0934267B1 (https=)
JP (1) JP2001503400A (https=)
AT (1) ATE212619T1 (https=)
AU (1) AU4812697A (https=)
CA (1) CA2268418A1 (https=)
DE (1) DE69710204T2 (https=)
ES (1) ES2171905T3 (https=)
WO (1) WO1998017645A1 (https=)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9702088D0 (en) 1997-01-31 1997-03-19 Pharmacia & Upjohn Spa Matrix metalloproteinase inhibitors
EP0977733B1 (en) * 1997-02-03 2003-09-03 Pfizer Products Inc. Arylsulfonylamino hydroxamic acid derivatives
KR100352316B1 (ko) 1997-07-31 2002-09-12 더 프록터 앤드 갬블 캄파니 메탈로프로테아제억제제로서사용되는술포닐아미노치환히드록삼산유도체
WO2000037433A1 (en) * 1998-12-18 2000-06-29 Abbott Laboratories Inhibitors of matrix metalloproteinases
BR0007784A (pt) 1999-01-27 2002-02-05 American Cyanamid Co Composto, método para inibir mudanças patológicas mediadas pela enzima que converte o tnf-alfa (tace) em um mamìfero, composição farmacêutica, e, processo para preparar um composto
US6225311B1 (en) * 1999-01-27 2001-05-01 American Cyanamid Company Acetylenic α-amino acid-based sulfonamide hydroxamic acid tace inhibitors
US6313123B1 (en) 1999-01-27 2001-11-06 American Cyanamid Company Acetylenic sulfonamide thiol tace inhibitors
US6200996B1 (en) 1999-01-27 2001-03-13 American Cyanamid Company Heteroaryl acetylenic sulfonamide and phosphinic acid amide hydroxamic acid tace inhibitors
US6277885B1 (en) 1999-01-27 2001-08-21 American Cyanamid Company Acetylenic aryl sulfonamide and phosphinic acid amide hydroxamic acid TACE inhibitors
US6762178B2 (en) 1999-01-27 2004-07-13 Wyeth Holdings Corporation Acetylenic aryl sulfonamide and phosphinic acid amide hydroxamic acid TACE inhibitors
US6326516B1 (en) 1999-01-27 2001-12-04 American Cyanamid Company Acetylenic β-sulfonamido and phosphinic acid amide hydroxamic acid TACE inhibitors
US6753337B2 (en) 1999-01-27 2004-06-22 Wyeth Holdings Corporation Alkynyl containing hydroxamic acid compounds as matrix metalloproteinase/tace inhibitors
US6946473B2 (en) * 1999-01-27 2005-09-20 Wyeth Holdings Corporation Preparation and use of acetylenic ortho-sulfonamido and phosphinic acid amido bicyclic heteroaryl hydroxamic acids as TACE inhibitors
US6340691B1 (en) 1999-01-27 2002-01-22 American Cyanamid Company Alkynyl containing hydroxamic acid compounds as matrix metalloproteinase and tace inhibitors
HK1044935A1 (zh) 1999-03-03 2002-11-08 The Procter & Gamble Company 双异取代的金属蛋白酶抑制剂
KR20010102486A (ko) 1999-03-03 2001-11-15 데이비드 엠 모이어 알케닐- 및 알키닐-함유 메탈로프로테아제 저해제
SE0100903D0 (sv) * 2001-03-15 2001-03-15 Astrazeneca Ab Compounds
SE0100902D0 (sv) * 2001-03-15 2001-03-15 Astrazeneca Ab Compounds
JP2005507937A (ja) * 2001-11-01 2005-03-24 ワイス・ホールディングズ・コーポレイション マトリックスメタロプロテイナーゼおよびtace阻害剤としてのアレンアリールスルホンアミドヒドロキサム酸
SE0103710D0 (sv) * 2001-11-07 2001-11-07 Astrazeneca Ab Compounds
MXPA04011767A (es) * 2002-05-29 2005-03-31 Merck & Co Inc COMPUESTOS UTILES EN EL TRATAMIENTO DE áNTRAX E INHIBIDORES DEL FACTOR LETAL.
SE0202539D0 (sv) * 2002-08-27 2002-08-27 Astrazeneca Ab Compounds
GB0221246D0 (en) * 2002-09-13 2002-10-23 Astrazeneca Ab Compounds
US7199155B2 (en) * 2002-12-23 2007-04-03 Wyeth Holdings Corporation Acetylenic aryl sulfonate hydroxamic acid TACE and matrix metalloproteinase inhibitors
EP2181704B1 (en) 2002-12-30 2015-05-06 Angiotech International Ag Drug delivery from rapid gelling polymer composition
BRPI0407587A (pt) * 2003-02-18 2006-02-14 Pfizer inibidores do vìrus da hepatite c, composições e tratamentos que os utilizam
US7652036B2 (en) * 2003-02-25 2010-01-26 Topotarget Uk Limited Carbamic acid compounds comprising a bicyclic heteroaryl group as HDAC inhibitors
EP1747212A4 (en) * 2004-05-11 2009-03-25 Merck & Co Inc PROCESS FOR THE PREPARATION OF N-SULFONATED AMINOIC DERIVATIVES
SE0401762D0 (sv) * 2004-07-05 2004-07-05 Astrazeneca Ab Novel compounds
US7648992B2 (en) 2004-07-05 2010-01-19 Astrazeneca Ab Hydantoin derivatives for the treatment of obstructive airway diseases
ITFI20040174A1 (it) 2004-08-03 2004-11-03 Protera S R L Derivati arilsolfonammidici dell'acido idrossammico ad azione inibitoria di metalloproteinasi
US20100003276A1 (en) * 2004-12-07 2010-01-07 Hermes Jeffery D Methods for treating anthrax and inhibiting lethal factor
SE0403085D0 (sv) * 2004-12-17 2004-12-17 Astrazeneca Ab Novel componds
SE0403086D0 (sv) * 2004-12-17 2004-12-17 Astrazeneca Ab Compounds
TW200831488A (en) * 2006-11-29 2008-08-01 Astrazeneca Ab Novel compounds
RU2748835C1 (ru) 2017-11-27 2021-05-31 Совет Научных И Прикладных Исследований Индол(сульфонил)-n-гидроксибензамидные производные в качестве селективных ингибиторов hdac

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5646167A (en) * 1993-01-06 1997-07-08 Ciba-Geigy Corporation Arylsulfonamido-substituted hydroxamix acids
US5455258A (en) * 1993-01-06 1995-10-03 Ciba-Geigy Corporation Arylsulfonamido-substituted hydroxamic acids
JPH10501806A (ja) * 1994-06-22 1998-02-17 ブリティッシュ バイオテック ファーマシューティカルズ リミテッド 金属タンパク質分解酵素阻害剤
EP0800449B1 (de) * 1995-01-03 1999-07-07 Reinhard Eichenberger Verfahren und vorrichtung zur herstellung von verstärkungseinlagen für werkstoffverbunde, insbesondere schleif- oder trennscheiben
US5863949A (en) * 1995-03-08 1999-01-26 Pfizer Inc Arylsulfonylamino hydroxamic acid derivatives
DK0821671T3 (da) * 1995-04-20 2001-04-23 Pfizer Arylsulfonylhydroxamsyrederivater som MMP- og TNF-inhibitorer
KR980009238A (ko) * 1995-07-28 1998-04-30 우에노 도시오 설포닐아미노산 유도체
DK0757984T3 (da) * 1995-08-08 2003-03-03 Ono Pharmaceutical Co Hydroxamsyrederivater, der kan anvendes til inhibering af gelatinase
RU2164914C2 (ru) * 1995-11-13 2001-04-10 Хехст Акциенгезелльшафт ЦИКЛИЧЕСКИЕ И ГЕТЕРОЦИКЛИЧЕСКИЕ N-ЗАМЕЩЕННЫЕ α-ИМИНОГИДРОКСАМОВЫЕ И КАРБОНОВЫЕ КИСЛОТЫ
CN100413859C (zh) * 1996-01-23 2008-08-27 盐野义制药株式会社 磺化的氨基酸衍生物及含有它的金属蛋白酶抑制剂

Also Published As

Publication number Publication date
EP0934267A1 (en) 1999-08-11
WO1998017645A1 (en) 1998-04-30
EP0934267B1 (en) 2002-01-30
ES2171905T3 (es) 2002-09-16
DE69710204D1 (en) 2002-03-14
DE69710204T2 (de) 2002-10-24
US5804593A (en) 1998-09-08
CA2268418A1 (en) 1998-04-30
JP2001503400A (ja) 2001-03-13
AU4812697A (en) 1998-05-15

Similar Documents

Publication Publication Date Title
ATE212619T1 (de) Alpha-amino sulfonyl hydroxamsäure als matrix metalloproteinase inhibitoren
DE69809187D1 (de) Metalloproteinase-Inhibitoren
DE69737605D1 (de) Sulfonierte aminosäurederivate und metalloproteinase-inhibitoren, die diese enthalten
EA200201057A1 (ru) Новый способ синтеза периндоприла и его фармацевтически приемлемых солей
AR097445A2 (es) Ésteres oxigenados de ácidos 4-yodo fenilamino benzhidroxámicos
EA199900366A1 (ru) Гетероарильные производные сукцинамидов и их применение в качестве ингибиторов металлопротеиназы
ES2109218T3 (es) Bis-(hidroximetil)ciclobutil-purinas y -pirimidinas.
EA200300067A1 (ru) Кристаллическая форма целекоксиба
DK1001930T3 (da) N-hydroxyformamidderivater som inhibitorer af matrix-metalloproteinaser
DK0464465T3 (da) Substituerede aminoalkylbiphenylderivater, antimykotiske præparater indeholdende disse derivater og mellemprodukter til fremstilling deraf
DK220386D0 (da) 2-(4-benzoyl-1-piperidinyl)-alkanolderivater, fremgangsmaade til fremstilling af saadanne derivater og anvendelse af disse som laegemidler
UY24919A1 (es) Compuestos amínicos sustituidos, procedimiento de preparación, y su aplicación
DK1037868T3 (da) Alfa-Hydroxy-, amino- og halogenderivater af beta-sulfonylhydroxamsyrer som matrixmetalloproteinaseinhibitorer
NO20063090L (no) Amidopyrazolderivater
CO5540284A2 (es) Sulfonamidas
ES2485867T3 (es) Compuestos opioides de carboxamido
NO984481D0 (no) 4-((thien-3-yl)metyl) imidazolderivater med <alfa>-2-adrenoceptor agonistisk aktivitet
FI833075A0 (fi) 2-nitro-1,1-etendiaminer, foerfaranden foer deras framstaellning och deras anvaendning som laekemed
ATE356114T1 (de) Inhibitoren von metalloproteinasen
EA199800189A1 (ru) Оптически активное производное фенилпиримидина в качестве анальгетика
FI861045A0 (fi) B-laktamantibiotika, foerfarande foer deras framstaellning och deras anvaendning som laekemedel.
EA199900809A1 (ru) Производные 2-(замещенный бензоил) циклоакил-1-карбоновой кислоты
NO308249B1 (no) Nye indan-2-mercaptoacetylamid-disulfidderivater som er anvendbare som inhibitorer av enkefalinase
DE69711221D1 (de) Metalloproteinase-inhibitoren
NO20050766L (no) Sulfonylpiperidinderivater som inneholder en aryl- eller heteroarylgruppe til anvendelse som matriksmetalloproteinaseinhibitor

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties